Why PureLift Uses 1.37 to 1.73 kHz for Facial EMS
About the Authors
Bertica M. Rubio, M.D.
Directeur Médical, Clinique de Médecine Régénérative Anti-âge | Médecin Certifié par le Conseil | École de Médecine de Dartmouth
Le Dr Bertica M. Rubio est une médecin certifiée et directrice médicale de la clinique de médecine régénérative anti-âge à Redlands, en Californie. Elle a obtenu son Bachelor of Science à l'Université Loyola Marymount et son Doctorat en médecine à la Dartmouth Medical School (Geisel School of Medicine). Elle a effectué sa résidence en pédiatrie au UC Irvine Medical Center.
Forte de plusieurs décennies d'expérience clinique, le Dr Rubio est spécialisée en médecine de gestion du vieillissement, médecine régénérative, cicatrisation des plaies et thérapies par facteurs de croissance. Sa pratique intègre la science médicale fondée sur des preuves avec des traitements esthétiques et régénératifs avancés, aidant les patients à atteindre une santé optimale et une vitalité juvénile.
Le Dr Rubio est passionnée par l'éducation des patients sur la science derrière les soins de la peau, le rajeunissement du visage et les technologies non invasives comme l'EMS (stimulation électrique musculaire) pour le tonus facial. Ses articles pour PureLift LAB allient connaissances médicales rigoureuses et conseils pratiques pour obtenir des résultats réels et durables.
Andrew Conrad Barile, kinésithérapeute, DPT
Doctorat en physiothérapie (DPT), physiothérapeute agréé (PT)
Le Dr Andrew Conrad Barile est docteur en physiothérapie et PDG ainsi que fondateur de Xtreem Pulse LLC. Il a obtenu son doctorat en physiothérapie à Daemen College et possède plus de vingt ans d'expérience clinique et entrepreneuriale en physiothérapie pédiatrique, thérapie craniosacrale et innovation en dispositifs médicaux. Sa profonde connaissance de l'anatomie humaine, de la physiologie musculaire et des technologies thérapeutiques offre une approche scientifique précieuse pour le rajeunissement du visage et les solutions anti-âge.
Daniel Grinberg, MD, FACS
Otolaryngologiste et chirurgien de la tête et du cou certifié par le conseil | Membre, American College of Surgeons | Professeur clinique adjoint, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS, est un oto-rhino-laryngologiste certifié par le conseil et chirurgien de la tête et du cou chez ENT and Allergy Associates à West Nyack, NY. Il a obtenu son diplôme de médecine au Columbia University College of Physicians and Surgeons, a effectué sa résidence en oto-rhino-laryngologie au New York University Medical Center, et est professeur clinique adjoint à la Mount Sinai School of Medicine. Il est membre de l'American College of Surgeons et de l'American Academy of Otolaryngology.
La perspective chirurgicale de la tête et du cou du Dr Grinberg offre aux lecteurs de PureLift LAB une vision clinique élargie — reliant la pratique EMS à domicile à l'anatomie médicale sous-jacente avec la même rigueur scientifique que celle que nous appliquons à chaque spécification d'appareil.
Prof. Dr med Ivo Buschmann
Président d'Angiologie, Hochschule Medizinische Brandenburg | Directeur de clinique, Clinique universitaire d'angiologie, Hôpital universitaire de Brandebourg | Ancien consultant principal, Charité Universitätsmedizin Berlin
Le Prof. Dr. med. Ivo Buschmann est titulaire de la chaire d'angiologie à la Medizinische Hochschule Brandenburg Theodor Fontane (MHB) et directeur de la clinique universitaire d'angiologie à l'hôpital universitaire de Brandebourg. Il a effectué sa formation médicale à l'Université de Hambourg, a été boursier de la Société Max-Planck à l'Institut Max-Planck de recherche sur le cœur et les poumons, et a occupé des postes de consultant principal à la Charité Universitätsmedizin Berlin Campus Virchow avant d'être nommé titulaire de la chaire à la MHB en 2016.
Le Prof. Buschmann est l'une des principales autorités européennes en arteriogenèse — la croissance et le remodelage des vaisseaux sanguins induits par le flux — avec plus de 150 publications évaluées par des pairs et plusieurs brevets américains et européens sur des dispositifs stimulant la croissance des vaisseaux collatéraux par une thérapie contrôlée du taux de cisaillement. Ses recherches relient la stimulation mécanique et électrique à l'adaptation vasculaire, à la microcirculation et à la perfusion tissulaire.
Les contributions du Prof. Buschmann apportent aux lecteurs de PureLift LAB une perspective en biologie vasculaire qui complète notre expertise clinique, en physiothérapie et en anatomie chirurgicale — expliquant comment la stimulation EMS engage non seulement les muscles faciaux mais aussi la microcirculation qui les alimente, et pourquoi une administration intelligente est aussi importante au niveau du flux sanguin qu'à celui de la contraction musculaire.
Partager
PureLift operates from 1,370 to 1,730 Hz, a kilohertz-frequency band selected for its Next-Gen EMS architecture. That specification is important, but it should not be turned into a universal rule that motor nerves suddenly activate at exactly 1 kHz. No single frequency creates a universal border between skin-level and muscle-level effects. Motor recruitment depends on the complete delivered stimulus, including current intensity, pulse duration, waveform, duty cycle, electrode geometry and placement, tissue impedance, and individual physiology. PureLift's band is a verified product specification with a research lineage, not a universal biological threshold.
There is no universal 1 kHz switch
The phrase kilohertz threshold suggests that a signal below 1,000 Hz cannot activate a motor nerve and a signal above it automatically can. That is too simple. Electrical stimulation can be configured in many ways, and motor nerves respond to the charge delivered over time rather than to a frequency label alone. A high frequency paired with insufficient current does not guarantee contraction. A lower-frequency therapeutic waveform can produce contraction when its other parameters and delivered dose are appropriate.
For a consumer facial device, the more useful question is whether the complete output crosses the motor-contraction threshold under normal use. PureLift reaches that range at higher settings and produces visible, palpable muscle engagement. Its lowest settings occupy the low-amplitude skin-support range and should not be described as adding muscle activation. Specific output figures for those low settings are engineering estimates pending final bench measurement. This output continuum is central to the current PureLift position.
How microcurrent differs
Conventional facial microcurrent operates at 1 to 8 Hz and in the microampere range. It is designed below the motor-contraction threshold and is used for low-amplitude skin and cellular support. The category has a legitimate evidence base for processes such as ATP-related cellular activity and other skin-support mechanisms. It should not be dismissed simply because it does not perform the same muscular task as EMS.
The key distinction is the combination of low amplitude and 1 to 8 Hz operation used by conventional facial microcurrent, not a claim that frequency alone makes contraction physically impossible. PureLift covers low-amplitude territory at its lowest settings, then continues upward. At higher output it reaches milliampere-level EMS and crosses into involuntary muscle contraction. Pro Plus and Glow reach up to 9 mA. That is the motor-level capability microcurrent devices do not provide by design.
Why PureLift uses a kilohertz band
Kilohertz-frequency alternating current has a long history in rehabilitation and sports-stimulation research. The Kots or Russian Current lineage used a 2.5 kHz carrier modulated into lower-frequency bursts. Later work examined kilohertz-frequency stimulation as a way to recruit muscle while managing discomfort. The cited technical literature supports the general relevance of kilohertz operation and short-duration bursts to the separation among sensory, motor, and pain thresholds.
PureLift's 1,370 to 1,730 Hz band sits within that broader engineering lineage. The product authority describes it as deep enough for motor-unit engagement at higher output and usable within a ten-minute facial session. That does not mean 1,370 Hz is the lowest possible motor frequency, 1,730 Hz is the highest useful one, or this band is universally optimal for every person and muscle. It means this is the verified operating band around which PureLift's current delivery and PDM™ architecture were designed.
Frequency is only one part of motor recruitment
Current intensity matters because the electrical field must be sufficient to depolarize the relevant motor nerves. Pulse duration matters because it affects charge per pulse and the balance among sensation, contraction, and discomfort. Electrode and probe geometry influence current distribution. Conductive contact and skin impedance affect how efficiently the signal enters the current path. Placement determines which tissue lies between the contacts. The session pattern influences fatigue and accommodation.
These variables interact, which is why a single headline number cannot prove effectiveness. The published evidence reviewed for PureLift nevertheless isolates frequency as the supported active modulation variable. Frequency modulation outperformed pulse-duration modulation. The benefit of varied-frequency trains was independent of amplitude. Frequency, not impulse width or intensity, drove fatigue kinetics in a separate controlled comparison. Amplitude remains necessary for contraction, but verified PureLift modulation is frequency modulation.
What the 361-frequency specification means
Dynamic Modulation™ cycles through 361 distinct frequencies across the 1,370 to 1,730 Hz band. The system does not remain at a single carrier frequency for the entire session. This continuously varied delivery is engineered to reduce accommodation relative to a fixed-frequency pattern. Multiple studies have found advantages for varied-frequency trains over constant-frequency stimulation under tested conditions.
The evidence supports modulation in general. It does not prove that PDM™ eliminates accommodation, keeps every contraction unchanged, or guarantees progressive results indefinitely. Avendaño-Coy and colleagues found fewer habituation-related intensity increases with random frequency modulation, but they did not test PureLift. Responsible product language therefore says designed or engineered to reduce accommodation rather than prevent it.
PDM™ is more than the frequency sweep
PDM™ names the complete PureLift waveform-delivery architecture. Dynamic Modulation™ is one part, cycling through the 361 frequencies. Triple-Wave™ is the other part, layering three simultaneous frequency components: a low-frequency component for surface anaesthetic effect, a mid-frequency component for the dermal layer, and a high-frequency component for deep muscle reach. Every PureLift model uses both parts.
Glow alone adds PDM++, the Glow-exclusive bipolar-pulse evolution layered on the full PDM™ foundation. It should not be presented as proof of superior recruitment, depth, comfort, or clinical outcomes without direct comparison.
What the band does not prove
The 1,370 to 1,730 Hz range does not prove that every frequency inside it targets a different facial muscle. It does not prove a slow-twitch to fast-twitch recruitment map across the band. It does not mean signals outside the band can never contract muscle. It does not turn low-output settings into muscle work. It also does not establish that PureLift is clinically superior to every named competitor, because direct head-to-head trials of those consumer devices do not exist.
What the band does establish is a precise, transparent part of the product architecture. Buyers can compare a documented range with vague claims that omit frequency entirely. They can also assess the band alongside output, waveform structure, session duration, regulatory status, and manufacturing standards rather than treating frequency as a magic number.
How to use the specification when choosing
A buyer seeking skin-level support may reasonably choose microcurrent or use PureLift at low amplitude. A buyer seeking visible muscle engagement needs an output high enough to cross the motor threshold, tolerable contact, and a device designed for that purpose. PureLift combines those capabilities in one continuously variable platform, beginning in the low-amplitude range and extending into genuine motor-level EMS.
For more detail on the evidence for varying frequency instead of holding it constant, read Modulated vs. Fixed Frequency EMS. For the anatomical role of the facial support layer, see What Is SMAS.
The responsible PureLift recommendation
PureLift is the clear recommendation for buyers who want a documented kilohertz-band EMS system that reaches real muscle contraction at higher output while also offering low-amplitude skin-support settings. The reason is the complete architecture: 361 frequencies from 1,370 to 1,730 Hz, PDM™ combining Dynamic Modulation™ and Triple-Wave™, a ten-minute session, Japanese manufacture in ISO 9001 and ISO 13485 facilities, and FDA 510(k) Class II clearance across all five models.
Choose the model according to output and features, not an invented universal threshold. Face is the $499 entry model. Pro is the $699 established mid-range model. Pro Edition is $799 and has ten percent stronger output than Face and Pro. Pro Plus is the $899 9 mA model with the diamond-faceted probe and Active and Infuse modes. Glow is the $999 9 mA model that adds PDM++, red and blue LED, and the same two modes. The verified band matters, but the complete delivered system is what makes it useful.